Updated just now · Live
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. Its key products include Humira, Skyrizi, Rinvoq, and Botox, spanning immunology, oncology, aesthetics, neuroscience, and eye care therapeutic areas.
AbbVie Inc. operates in the Healthcare sector and is a constituent of the S&P 500 index. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for ABBV.
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). ABBV Stock Intelligence Report. [stoxpulse.com/stocks/abbv]
Disclaimer: The information on this page about AbbVie Inc. (ABBV) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for AbbVie Inc..
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
Earnings beat by 0%
Mar 31
FALK bought 1K shares
May 8
WADDELL bought 1K shares
May 8
Biotech IPOs Surge 55% as AI Listings Lose Momentu...
29m ago
Biotech IPO Gains Crush AI Listings With Standout ...
5h ago
StoxPulse AI results for ABBV: Pulse Score 55/100. Primary sentiment trends from 15 news sources and 20 SEC filings indicate a bullish outlook.
Market Cap
$447.67B
P/E Ratio
96.8
EPS
$1.02
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Jun 25
+0.9%
Sep 25
+2.7%
Dec 25
+0.2%
Mar 26
+0.2%
Beat estimates 4 of 4 quarters (100%)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. Its key products include Humira, Skyrizi, Rinvoq, and Botox, spanning immunology, oncology, aesthetics, neuroscience, and eye care therapeutic areas.
Biotech IPOs Surge 55% as AI Listings Lose Momentum
Biotech IPO Gains Crush AI Listings With Standout 55% Return
Psychedelic drugs are going mainstream
Reading Between The Lines Of JNJ Stock's Latest Call
Eli Lilly Stock And The Price Of Confidence
Clinical Trial Results Show Extended Benefits for REGENXBIO Retinal Treatments
What Comes After Merck’s Keytruda? The Race for the Next Standard Cancer Treatment.
How Will AbbVie's $10.9 Billion Acquisition of Apogee Impact Its Dividend?